ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials: These clinical trials are currently enrolling patients at sites across the U.S. and will be opening clinical trial sites in Europe later this year.
Tue, 01 Oct 2024 17:00:00 GMT International communication and influence expert, Jose Ucar, was invited by the Anijie Global Foundation to be a speaker at the recent LEGIT NEXT GEN leadership program. Its aim was to empower leaders ...
Tue, 01 Oct 2024 05:29:00 GMT “We continue to execute our strategy and are pleased to complete the enrollment in two different trials in CHB and prostate cancer ... For more information, visit www.barinthusbio.com. This press ...
Tue, 01 Oct 2024 01:00:00 GMT We look forward to working with Curium to deliver these much-needed agents to prostate cancer patients in Japan as quickly as possible.” Chaitanya Tatineni, Curium's CEO International Markets ...
Mon, 30 Sep 2024 17:00:00 GMT In this section, you’ll find the latest Forbes press releases and news announcements. Forbes Media today announced that it will hold its 22nd edition of the Forbes Global CEO Conference in ...
Fri, 27 Sep 2024 06:16:00 GMT The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
